The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer
Joshua E. Meyer, MD, Fox Chase Cancer Center, Philadelphia, PA, explores some highlights from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the results of the Alliance A021501 study in pancreatic cancer, where the hypofractionated radiotherapy (RT) arm of the study was closed early. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
